Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | transthyretin |
GTO ID | GTC0695 |
Trial ID | 2021-001427-40 |
Disease | Familial Amyloid Polyneuropathy |
Altered gene | TTR |
Therapeutic/Target gene | Target gene |
Therapy | ASO |
Treatment | AKCEA-TTR-LRx|Eplontersen|ION-682884|IONIS-TTR-LRx|ION-682884|Wainua |
Location approved | US |
Phase | Phase3 |
Recruitment status | Ongoing |
Title | An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy |
Year | 2022 |
Country | Portugal |
Company sponsor | Ionis Pharmaceuticals, Inc. |
Vector information | |||
|
Cohort 1 | |||||||
|